到2029年全球哮喘藥物預測和市場分析

哮喘是一種常見的慢性肺部疾病，最常見於兒童期，可發生於任何年齡。它的特徵是慢性炎症，隨後氣道變窄，阻止空氣通過肺部。哮喘可以是持續性或間歇性的，嚴重程度可能有所不同。有一種逐步治療哮喘的方法，隨著疾病嚴重程度的增加，治療水平也隨之提高。由於哮喘是高度異質性疾病，因此這些靶向療法有多種不同的類型，其中一些目前處於後期開發階段。三重吸入療法預計將在預計的時間內增加患者的份額，以增加對中度至重度哮喘患者的適應性。

本報告涵蓋了非處方藥和後期管道哮喘治療的市場預測。我們還按嚴重程度對哮喘患者進行分類。以2019年為基準年，我們匯總了2020年至2029年的預測。

目錄

第1章目錄

• 表列表
• 圖列表

第2章哮喘：執行摘要

• 在預測期內，哮喘市場將保持保守增長
• GlaxoSmith Kline和Astra Zeneca牽頭
• 未滿足的重症哮喘患者需要圍繞診斷和治療選擇
• 後期開發計劃可滿足個性化和便捷藥品的需求
• 醫生的觀點

第3章簡介

• 促進因素
• 相關報告
• 未來相關報告

第4章疾病概述

• 病因與病理生理
  • 病因
  • 病理生理學
• 疾病嚴重程度分類

第5章流行病學

• 疾病背景
• 危險因素和合併症
• 全球和歷史趨勢
• 預測調查方法
  • 來源
  • 預測的前提條件和方法
• 哮喘的流行病學預測(2019-2029)
  • 終身診斷哮喘患病率
  • 按年齡患病率對哮喘的終生診斷
  • 性別一生對哮喘的診斷率
  • 嚴重程度哮喘終生診斷率
• 討論
  • 瞭解流行病學預測
  • 分析極限
  • 分析優勢

第6章疾病管理

• 診斷和治療概述
  • 診斷
  • 治療指南和臨床實踐
• 美國
• 歐盟5個國家
• 日本

第7章競爭力評估

• 概述

第8章需求和機會評估

• 概述
• 準確的診斷
• 嚴重哮喘的個性化治療
• 改善患者兼容性
• 減少治療費用

第9章管道評估

• 概述
• 臨床開發中有希望的藥物
  • 胸間質磷脂生成素抑製劑
  • CRTH2拮抗劑
  • 吸入皮質類固醇/長效Beta激動劑/長效毒蕈鹼拮抗劑
• 其他正在開發的藥物

第10章，當前和將來的玩家

• 概述
• 企業戰略趨勢
• AstraZeneca
• Novartis
• Roche/Genentech
• GlaxoSmithKline
• Teva
• Boehringer Ingelheim
• Merck
• Chiesi
• Regeneron/Sanofi
• AB Science SA

第11章市場前景

• 世界市場
  • 預測
  • 驅動因素和壁壘-世界問題
• 美國
  • 預測
  • 重要事件
  • 增長因素和障礙
• 歐盟5個國家
  • 預測
  • 重要事件
  • 增長因素和障礙
• 日本
  • 預測
  • 重要事件
  • 增長因素和障礙

第12章附錄

Asthma - Global Drug Forecast and Market Analysis to 2029

Asthma is a common chronic lung disease that most often develops during childhood, although it can occur at any age. It is characterized by chronic inflammation and subsequent narrowing of the airways, which obstructs the passage of air through the lungs. Asthma can be persistent or intermittent, and also varies in severity. The treatment of asthma involves a step-wise approach, where the level of therapy increases as the disease severity increases. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies, of which some are currently in the late-stage pipeline. Triple inhaled therapies are forecasted to grow in patient share over the forecasted period to increase compliance rates amongst moderate to severe asthma patients.

This model covers the market forecast for the marketed and late-stage pipeline asthma therapeutics. The model segments asthma patients by severity. The base year of this model is 2019, and the forecast period is 2020-2029.

Key Highlights

• The greatest drivers of growth in the global asthma market include the launch of six new pipeline therapies during the forecast period and an increasing diagnosed prevalence in many 7MM countries.
• The main barriers to growth in the asthma market include high genericization of historical drug classes.
• Late-stage pipeline products in the ICS/LABA/LAMA triple-therapy fixed dose inhalers, CRTH2 antagonists, and ICS/SABA double therapies are emerging as distinct drug classes in the field.
• The most important unmet needs in the asthma market are improved drug compliance and personalized therapy for the most severe patients.

KEY QUESTIONS ANSWERED

• Which unmet needs are limiting the treatment of asthma in the 7MM?
• What strategies can the pharmaceutical industry employ to increase treatment rates for asthma? How should these strategies differ across different geographical markets?
• What effect will the launch of generics have on the sales of branded agents?
• What are the main R&D trends in the asthma market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?

Scope

• Overview of asthma including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Topline asthma market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
• Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting asthma therapeutics sales in the 7MM.
• Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global asthma therapeutics market from 2019-2029.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Asthma: Executive Summary

• 2.1 Asthma Market to Experience Conservative Growth Over the Forecast Period
• 2.2 GlaxoSmithKline and AstraZeneca Lead the Way
• 2.3 Unmet Needs Remain Surrounding Asthma Diagnosis and Treatment Options for Severe Patients
• 2.4 Late-Stage Pipeline Addresses Needs for Personalized and Convenient Medications
• 2.5 What Do Physicians Think?

3 Introduction

• 3.1 Catalyst
• 3.2 Related Reports
• 3.3 Upcoming Related Reports

4 Disease Overview

• 4.1 Etiology and Pathophysiology
  • 4.1.1 Etiology
  • 4.1.2 Pathophysiology
• 4.2 Classification of Disease Severity

5 Epidemiology

• 5.1 Disease Background
• 5.2 Risk Factors and Comorbidities
• 5.3 Global and Historical Trends
• 5.4 Forecast Methodology
  • 5.4.1 Sources
  • 5.4.2 Forecast Assumptions and Methods
• 5.5 Epidemiological Forecast for Asthma (2019-2029)
  • 5.5.1 Lifetime Diagnosed Prevalent Cases of Asthma
  • 5.5.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Asthma
  • 5.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Asthma
  • 5.5.4 Lifetime Diagnosed Prevalent Cases of Asthma by Severity
• 5.6 Discussion
  • 5.6.1 Epidemiological Forecast Insight
  • 5.6.2 Limitations of Analysis
  • 5.6.3 Strengths of Analysis

6 Disease Management

• 6.1 Diagnosis and Treatment Overview
  • 6.1.1 Diagnosis
  • 6.1.2 Treatment Guidelines and Clinical Practice
• 6.2 US
• 6.3 5EU
• 6.4 Japan

7 Competitive Assessment

• 7.1 Overview

8 Needs and Opportunity Assessment

• 8.1 Overview
• 8.2 Accurate Diagnosis
• 8.3 Personalized Therapies for Severe Asthma
• 8.4 Increased Patient Compliance
• 8.5 Lower Cost of Therapy

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising Drugs in Clinical Development
  • 9.2.1 Thymic Stromal Lymphopoietin Inhibitors
  • 9.2.2 CRTH2 Antagonist
  • 9.2.3 Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist
• 9.3 Other Drugs in Development

10 Current and Future Players

• 10.1 Overview
• 10.2 Trends in Corporate Strategy
• 10.3 AstraZeneca
• 10.4 Novartis
• 10.5 Roche/Genentech
• 10.6 GlaxoSmithKline
• 10.7 Teva
• 10.8 Boehringer Ingelheim
• 10.9 Merck
• 10.10 Chiesi
• 10.11 Regeneron/Sanofi
• 10.12 AB Science SA

11 Market Outlook

• 11.1 Global Markets
  • 11.1.1 Forecast
  • 11.1.2 Drivers and Barriers - Global Issues
• 11.2 US
  • 11.2.1 Forecast
  • 11.2.2 Key Events
  • 11.2.3 Drivers and Barriers
• 11.3 5EU
  • 11.3.1 Forecast
  • 11.3.2 Key Events
  • 11.3.3 Drivers and Barriers
• 11.4 Japan
  • 11.4.1 Forecast
  • 11.4.2 Key Events
  • 11.4.3 Drivers and Barriers

12 Appendix

List of Tables

List of Tables

• Table 1: Asthma: Key Metrics in the 7MM
• Table 2: Classification of Asthma by Severity
• Table 3: Risk Factors and Comorbidities for Asthma
• Table 4: Treatment Guidelines for Asthma across the 7MM
• Table 5: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
• Table 6: Country Profile - US
• Table 7: Country Profile - 5EU
• Table 8: Country Profile - Japan
• Table 9: Leading Treatments for Asthma, 2020
• Table 10: AstraZeneca's Asthma Portfolio Assessment, 2020
• Table 11: Novartis' Asthma Portfolio Assessment, 2020
• Table 12: Roche/Genentech Asthma Portfolio Assessment, 2020
• Table 13: GlaxoSmithKline's Asthma Portfolio Assessment, 2020
• Table 14: Teva's Asthma Portfolio Assessment, 2020
• Table 15: Boehringer Ingelheim's Asthma Portfolio Assessment, 2020
• Table 16: Merck's Asthma Portfolio Assessment, 2020
• Table 17: Chiesi's COPD Portfolio Assessment, 2019
• Table 18: Regeneron/Sanofi's Asthma Portfolio Assessment, 2020
• Table 19: AB Science Asthma Portfolio Assessment, 2020
• Table 20: Asthma Market - Global Drivers and Barriers, 2019-2029
• Table 21: Key Events Impacting Sales for Asthma in the US, 2019-2029
• Table 22: Asthma Market - Drivers and Barriers in the US, 2019-2029
• Table 23: Key Events Impacting Sales for Asthma in the 5EU, 2019-2029
• Table 24: Asthma Market - Drivers and Barriers in the 5EU, 2019-2029
• Table 25: Key Events Impacting Sales for Asthma in Japan, 2019-2029
• Table 26: Asthma Market - Global Drivers and Barriers in Japan, 2019-2029
• Table 27: Key Historical and Projected Launch Dates for Asthma
• Table 28: Key Historical and Projected Patent Expiry Dates for Asthma
• Table 29: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

• Figure 1: Global Sales Forecast by Country for Asthma in 2019 and 2029
• Figure 2: Analysis of the Company Portfolio Gap in Asthma During the Forecast Period
• Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for Asthma, 2020